HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by equities research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a report on Tuesday, May 20th. Morgan Stanley restated an “equal weight” rating and issued a $40.00 price target (down previously from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Mizuho reduced their price target on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 18th. Cantor Fitzgerald restated a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Finally, BMO Capital Markets cut shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $120.00 to $70.00 in a research report on Monday, June 16th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $60.88.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded down $0.23 on Wednesday, reaching $17.23. The company’s stock had a trading volume of 6,649,704 shares, compared to its average volume of 2,124,661. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The stock has a market capitalization of $1.69 billion, a P/E ratio of -6.41 and a beta of 0.61. The stock’s 50 day simple moving average is $40.94 and its two-hundred day simple moving average is $80.65. Sarepta Therapeutics has a 12-month low of $16.99 and a 12-month high of $162.95.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period in the prior year, the firm earned $0.73 EPS. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. Research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Inspire Investing LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Sarepta Therapeutics by 54.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock worth $29,570,000 after purchasing an additional 164,041 shares during the period. United Services Automobile Association acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $436,000. Great Lakes Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $224,000. Finally, Scientech Research LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $968,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.